Quick Answer
Century Therapeutics, Inc. reported Total Revenue of $109.16 million for fiscal year 2025.
Century Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $109.16M +1556.8% |
$6.59M +194.8% |
$2.23M -57.0% |
$5.20M | — | — |
| Revenue (ASC 606) | $109.16M +1556.8% |
$6.59M +194.8% |
$2.23M -57.0% |
$5.20M | — | — |
| Net Income | -$9.58M +92.4% |
-$126.57M +7.4% |
-$136.67M -4.4% |
-$130.93M -36.6% |
-$95.82M -78.9% |
-$53.58M |
| Diluted EPS | -$0.14 +91.3% |
-$1.61 +30.0% |
-$2.30 +22.3% |
-$2.96 +0.0% |
-$2.96 +58.7% |
-$7.16 |
| Total Assets | $223.70M -36.7% |
$353.22M -2.1% |
$360.69M -25.9% |
$486.54M +11.2% |
$437.38M +309.6% |
$106.78M |
| Cash and Equivalents | $61.85M +5.8% |
$58.44M +23.5% |
$47.32M -43.8% |
$84.27M +49.3% |
$56.45M +107.4% |
$27.21M |
| Long-Term Debt | — | — | — | $3.74M -58.0% |
$8.90M -7.6% |
$9.64M |
| Stockholders Equity | $158.94M -1.5% |
$161.36M -12.7% |
$184.75M -39.0% |
$302.74M -23.6% |
$396.24M +472.4% |
-$106.41M -15.8% |
| R&D Expense | — | — | — | — | $75.65M +90.6% |
$39.68M |
| Operating Income | -$17.27M +87.5% |
-$138.14M +5.7% |
-$146.55M -9.5% |
-$133.83M -41.0% |
-$94.88M -76.0% |
-$53.90M |
| Shares Outstanding | 87.52M +2.0% |
85.84M +42.3% |
60.34M +9.7% |
55.01M -5.9% |
58.47M +681.5% |
7.48M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2025 | $109.16M | +12667.7% | +13700.8% |
| Revenue (ASC 606) | March 31, 2025 | $109.16M | +12667.7% | +13700.8% |
| Net Income | September 30, 2025 | -$34.42M | -10.2% | -5.8% |
| Diluted EPS | September 30, 2025 | -$0.40 | -8.1% | -5.3% |
| Total Assets | September 30, 2025 | $244.72M | -37.0% | -14.0% |
| Cash and Equivalents | September 30, 2025 | $55.52M | +5.6% | -2.4% |
| Long-Term Debt | December 31, 2022 | $3.74M | -58.0% | -39.1% |
| Stockholders Equity | September 30, 2025 | $176.35M | -9.9% | -16.0% |
| R&D Expense | September 30, 2021 | $19.55M | +80.8% | +3.2% |
| Operating Income | September 30, 2025 | -$36.12M | -3.8% | -4.2% |
| Shares Outstanding | September 30, 2025 | 86.53M | +2.3% | +0.2% |
- Century Therapeutics, Inc. reported Total Revenue of $109.16 million for fiscal year 2025.
- Century Therapeutics, Inc. showed an increase of +1556.8% in Total Revenue compared to the prior fiscal year.
- Century Therapeutics, Inc. reported Revenue (ASC 606) of $109.16 million for fiscal year 2025.
- Century Therapeutics, Inc. showed an increase of +1556.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Century Therapeutics, Inc. reported Net Income of -$9.58 million for fiscal year 2025.
- Century Therapeutics, Inc. showed an increase of +92.4% in Net Income compared to the prior fiscal year.
- Century Therapeutics, Inc. reported Diluted EPS of $0.14 per share (loss) for fiscal year 2025.
- Century Therapeutics, Inc. showed an increase of +91.3% in Diluted EPS compared to the prior fiscal year.
- Century Therapeutics, Inc. reported Total Assets of $223.70 million for fiscal year 2025.
- Century Therapeutics, Inc. showed a decrease of -36.7% in Total Assets compared to the prior fiscal year.
- Century Therapeutics, Inc. reported Cash and Equivalents of $61.85 million for fiscal year 2025.
- Century Therapeutics, Inc. showed an increase of +5.8% in Cash and Equivalents compared to the prior fiscal year.
- Century Therapeutics, Inc. reported Long-Term Debt of $3.74 million for fiscal year 2022.
- Century Therapeutics, Inc. showed a decrease of -58.0% in Long-Term Debt compared to the prior fiscal year.
- Century Therapeutics, Inc. reported Stockholders Equity of $158.94 million for fiscal year 2025.
- Century Therapeutics, Inc. showed a decrease of -1.5% in Stockholders Equity compared to the prior fiscal year.
- Century Therapeutics, Inc. reported R&D Expense of $75.65 million for fiscal year 2021.
- Century Therapeutics, Inc. showed an increase of +90.6% in R&D Expense compared to the prior fiscal year.
- Century Therapeutics, Inc. reported Operating Income of -$17.27 million for fiscal year 2025.
- Century Therapeutics, Inc. showed an increase of +87.5% in Operating Income compared to the prior fiscal year.
- Century Therapeutics, Inc. reported Shares Outstanding of 87.52 million shares for fiscal year 2025.
- Century Therapeutics, Inc. showed an increase of +2.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: